Trial Profile
An Open-label Study to Determine the Long-term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Nov 2023
Price :
$35
*
At a glance
- Drugs SAR 421869 (Primary)
- Indications Usher syndromes
- Focus Adverse reactions
- Sponsors Sanofi
- 09 May 2022 Planned End Date changed from 1 Jun 2032 to 13 Jun 2031.
- 09 May 2022 Planned primary completion date changed from 1 Jun 2032 to 13 Jun 2031.
- 10 Aug 2020 Planned End Date changed from 1 Jun 2031 to 1 Jun 2032.